<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width,initial-scale=1" />
<title>ILC vs IDC â€” Clinical, Molecular & Therapeutic Differences</title>
<style>
  :root{
    --bg:#0f172a;          
    --card:#111827;        
    --ink:#e5e7eb;         
    --muted:#94a3b8;       
    --ilc:#f59e0b;         
    --idc:#60a5fa;         
    --good:#10b981;        
    --warn:#f43f5e;        
    --row:#0b1223;         
  }
  *{box-sizing:border-box}
  body{
    margin:0; padding:28px;
    background:linear-gradient(135deg,#0b1020 0%, #0f172a 50%, #0b1020 100%);
    font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, "Helvetica Neue", Arial, "Apple Color Emoji","Segoe UI Emoji";
    color:var(--ink); line-height:1.45;
  }
  .wrap{
    max-width:1100px; margin:0 auto;
    background:linear-gradient(180deg, rgba(255,255,255,0.03), rgba(255,255,255,0.01));
    border:1px solid rgba(148,163,184,.25);
    border-radius:20px; box-shadow: 0 20px 50px rgba(0,0,0,.45);
    overflow:hidden;
  }
  header{
    padding:22px 22px 8px;
    display:flex; align-items:center; justify-content:space-between; gap:12px;
    background: radial-gradient(1200px 200px at 20% -40%, rgba(245,158,11,.15), transparent 70%),
               radial-gradient(900px 180px at 90% -30%, rgba(96,165,250,.15), transparent 70%);
    border-bottom:1px solid rgba(148,163,184,.25);
  }
  .title{font-size:22px; font-weight:800; letter-spacing:.2px;}
  .chips{display:flex; gap:8px; flex-wrap:wrap}
  .chip{
    border:1px solid rgba(148,163,184,.3);
    padding:6px 10px; border-radius:999px; font-size:12px; color:var(--muted);
    backdrop-filter: blur(6px);
  }
  .legend{display:flex; gap:8px; align-items:center}
  .badge{
    display:inline-flex; align-items:center; gap:6px;
    font-weight:700; padding:6px 10px; border-radius:10px; font-size:12px;
    color:#0b1020; background:white;
  }
  .badge.ilc{background: linear-gradient(135deg,#fde68a,#f59e0b); color:#1f2937}
  .badge.idc{background: linear-gradient(135deg,#93c5fd,#3b82f6); color:#0b1020}
  table{width:100%; border-collapse:separate; border-spacing:0;}
  th, td{padding:14px 16px; vertical-align:top; border-bottom:1px solid rgba(148,163,184,.18);}
  thead th{
    position:sticky; top:0; z-index:1;
    background:linear-gradient(180deg, rgba(17,24,39,.9), rgba(17,24,39,.85));
    backdrop-filter: blur(4px);
    text-align:left; font-size:14px; letter-spacing:.2px;
  }
  tbody tr:nth-child(odd){ background: var(--row);}
  .col-label{width:28%}
  .col-ilc, .col-idc{width:36%}
  .pill{
    display:inline-flex; align-items:center; gap:6px;
    border-radius:999px; padding:2px 8px; font-size:12px; font-weight:700;
    border:1px solid rgba(148,163,184,.25); color:var(--ink);
  }
  .pill.good{background: rgba(16,185,129,.12); border-color: rgba(16,185,129,.35)}
  .pill.warn{background: rgba(244,63,94,.12); border-color: rgba(244,63,94,.35)}
  .mini{display:inline-block; font-size:12px; color:var(--muted); margin-top:4px}
  .ref{padding:14px 22px; color:var(--muted); font-size:12px}
</style>
</head>
<body>
  <div class="wrap">
    <header>
      <div>
        <div class="title">ILC vs IDC â€” Differences & Therapeutic Implications</div>
        <div class="chips">
          <span class="chip">ğŸ§¬ CDH1 / E-cadherin</span>
          <span class="chip">ğŸŒ¸ ER-positive predominance</span>
          <span class="chip">ğŸ’Š AI & Trastuzumab decisions</span>
          <span class="chip">ğŸ§­ Metastatic tropism</span>
        </div>
      </div>
      <div class="legend">
        <span class="badge ilc">ğŸŸ¡ ILC</span>
        <span class="badge idc">ğŸ”µ IDC</span>
      </div>
    </header>

    <!-- âœ… Back-link goes here -->
    <p style="padding:12px"><a href="index.html">â¬…ï¸ Back to Surgery Home</a></p>

    <table role="table" aria-label="ILC vs IDC Comparison">
      <thead>
        <tr>
          <th class="col-label">ğŸ§© Category</th>
          <th class="col-ilc">ğŸŸ¡ ILC</th>
          <th class="col-idc">ğŸ”µ IDC</th>
          <th>ğŸ¯ Therapeutic Implications</th>
        </tr>
      </thead>
      <tbody>
        <!-- Clinical Presentation moved up -->
        <tr>
          <td>ğŸ©º Example Clinical Presentation</td>
          <td>ğŸ‘µ Postmeno, strongly <b>ER+</b>, subtle/asymmetric thickening; later GI/peritoneal spread ğŸ«„</td>
          <td>ğŸ¤ Palpable spiculated mass; later ğŸ¦´ bone pain</td>
          <td>ğŸ” ILC: consider <b>MRI</b> for extent, endocrine-first strategy</td>
        </tr>

        <tr>
          <td>ğŸ“Š Prevalence</td>
          <td>~10% of breast cancers</td>
          <td>Most common subtype</td>
          <td>ğŸ“ ILC underrepresented in trials â†’ avoid one-size-fits-all</td>
        </tr>

        <tr>
          <td>ğŸ”¬ Morphology</td>
          <td>â€œ<b>Single-file</b>â€ cells; hallmark = <b>E-cadherin loss</b> ğŸš«</td>
          <td>Cohesive nests/glands ğŸ§±</td>
          <td>Diagnostic marker; diffuse margins</td>
        </tr>

        <tr>
          <td>ğŸ§¬ Genomics</td>
          <td>â†‘ CDH1, PTEN loss/AKT â†‘, TBX3, FOXA1; â†“ GATA3</td>
          <td>More GATA3; rare CDH1 loss</td>
          <td>Different ER cofactors â†’ therapy response differs</td>
        </tr>

        <tr>
          <td>ğŸŒ¸ Hormone/Proliferation</td>
          <td>Mostly ER+, HER2â€“; low Ki-67 ğŸŒ¿</td>
          <td>Heterogeneous (A/B, HER2+, TNBC)</td>
          <td><span class="pill good">Endocrine-leaning</span> strategy</td>
        </tr>

        <tr>
          <td>ğŸ§­ Spread</td>
          <td>GI, peritoneum, ovaries â†‘</td>
          <td>Bone, lung, liver</td>
          <td>Tailor staging/surveillance</td>
        </tr>

        <tr>
          <td>ğŸ’‰ Chemo Response</td>
          <td>Lower pCR (3â€“5%) âš ï¸</td>
          <td>Higher pCR (~14%) âœ…</td>
          <td>Use chemo selectively in ILC</td>
        </tr>

        <tr>
          <td>ğŸ§ª Oncotype DX</td>
          <td>Rare high RS (~1.5%); many intermediate</td>
          <td>Up to 20% high RS</td>
          <td>Intermediate RS less informative</td>
        </tr>

        <tr>
          <td>ğŸ§¿ HER2 & Trastuzumab</td>
          <td>3â€“10%; trastuzumab effective</td>
          <td>15â€“20%; trastuzumab standard</td>
          <td>Test all ILC for HER2</td>
        </tr>

        <tr>
          <td>ğŸŒ¡ï¸ Endocrine Therapy</td>
          <td><b>AI (letrozole)</b> > tamoxifen</td>
          <td>AI advantage in luminal B</td>
          <td><span class="pill good">Prefer AI</span> in postmeno ILC</td>
        </tr>

        <tr>
          <td>ğŸ“‰ Prognosis</td>
          <td>Slow growing but risk late recurrence â³</td>
          <td>Chemo-sensitive, early pCR possible ğŸ’¥</td>
          <td>ILC: watch margins & atypical mets</td>
        </tr>

        <tr>
          <td>ğŸ§  Buzzwords</td>
          <td>â€œSingle-fileâ€ â€¢ â€œE-cadherinâˆ’â€ â€¢ â€œGI/peritoneal metsâ€ â€¢ â€œAI>TAMâ€</td>
          <td>â€œCohesive glandsâ€ â€¢ â€œGATA3â€ â€¢ â€œChemo-responsiveâ€</td>
          <td>Use to trigger recall ğŸš€</td>
        </tr>
      </tbody>
    </table>

    <div class="ref">
      ğŸ“š Source: Barroso-Sousa R, Metzger-Filho O. <i>Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications.</i> PMCID: PMC4952020, PMID: 27482285.
    </div>
  </div>
</body>
</html>
